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ABSTRACT
Objectives: The utility value attributed to taking pills
for prevention can have a major effect on the cost-
effectiveness of interventions, but few published
studies have systematically quantified this value. We
sought to quantify the utility value of taking pills used
for prevention of cardiovascular disease (CVD).
Design: Cross-sectional survey.
Setting: Central North Carolina.
Participants: 708 healthcare employees aged
18 years and older.
Primary and secondary outcomes: Utility values
for taking 1 pill/day, assessed using time trade-off,
modified standard gamble and willingness-to-pay
methods.
Results: Mean age of respondents was 43 years
(19–74). The majority of the respondents were female
(83%) and Caucasian (80%). Most (80%) took at least
2 pills/day. Mean utility values for taking 1 pill/day
using the time trade-off method were: 0.9972 (95% CI
0.9962 to 0.9980). Values derived from the standard
gamble and willingness-to-pay methods were 0.9967
(0.9954 to 0.9979) and 0.9989 (95% CI 0.9986 to
0.9991), respectively. Utility values varied little across
characteristics such as age, sex, race, education level
or number of pills taken per day.
Conclusions: The utility value of taking pills daily in
order to prevent an adverse CVD health outcome is
approximately 0.997.
BACKGROUND
The desire to take medicine is perhaps the
greatest feature which distinguishes man
from animals.—Sir William Osler
Many adults will face the decision about
whether to take some type of pill for prevent-
ive reasons at some point in their lives. When
people take pills, they go through a process
that involves, but is not limited to, obtaining
the pills, remembering to take the pills, and
ingesting the pills. These processes, part of
the routine of ‘taking pills’, can theoretically
affect quality of life, even apart from any
adverse effects of the medication itself. If the
pills require a prescription or therapeutic
monitoring, the process also includes visits to
clinicians and pharmacists, which may
further affect quality of life.
In assessing the potential value of prevent-
ive services, cost-effectiveness analyses
attempt to consider all the potential benefi-
cial and detrimental effects of the service,
including factors such as the effects of taking
a preventive medication daily on quality of
life. In such studies, these effects are often
measured by assigning a numerical value
that represents the relative quality of life
effect that a certain state of health carries
versus an ideal state of perfect health. This
numerical value is termed a ‘utility.’ Utilities
usually range from 0 to 1, with 0 represent-
ing death and 1 representing perfect health.
Using an accurate utility value for the effect
of taking a preventive medication is import-
ant, as relatively small changes in the utility
can have large effects on the cost-
effectiveness of the preventive service.1–3
Many studies have addressed the effect of
quantity and complexity of prescribed medi-
cation regimens on adherence, and many
others have attempted to quantify patient util-
ities for certain health conditions.4–6
However, based on our extensive literature
review (in July 2013), prior to conducting this
study, we were aware of only two studies that
included a systematic effort to quantify the
utility value of taking pills.7 8 In these two
Strengths and limitations of this study
▪ One of largest studies to quantify the utility of
pill-taking.
▪ Large sample permitted analysis of multiple
subgroups.
▪ Use of three different utility assessments.
▪ Respondents were predominantly women.
▪ Our sample was not representative of the general
population.
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studies, 57 and 70 patients were interviewed using the
time trade-off (TTO) utility assessment method. The inves-
tigators found a utility value of 0.998 for taking daily
aspirin in both studies, and 0.987 for taking warfarin
(including monitoring) in one study, and 0.988 for taking
warfarin in the second study. Additional studies cite a
utility value or discount value to taking pills,1–3 6 9–21
although some of these studies seem to have chosen values
arbitrarily, based on expert opinion, or based on other
published articles. A recent study estimated people’s
threshold for daily pill-taking by interviewing 360 people
in London, asking the amount of life they would need to
gain to take a daily pill for the rest of their life. They found
that the median amount of gain ‘required’ was 6 months,
with an IQR of 1–36 months.22
Given the limitations of previous studies, we sought to
better assess people’s utilities for pill-taking. In this
paper, we report the results of the first of two large cross-
sectional studies we conducted to quantify the utility of
taking pills for the purpose of trying to prevent a heart
attack or stroke, using three different methods: TTO,
standard gamble (SG) and willingness to pay (WTP).23
Second, we sought to understand whether the average
utility value varies by demographics and other character-
istics. This information would be useful for researchers
conducting cost-effectiveness analyses of preventive inter-
ventions that involve pill-taking, as well as to policymakers
who help determine which interventions will be accepted
for reimbursements by publicly funded programmes.
METHODS
Survey development
This cross-sectional study, conducted in April 2013, used
a survey to assess people’s utilities and was granted
exemption status by the Institutional Review Board of
the University of North Carolina.
To pretest and refine the utility assessment methods, we
used a single focus group of eight people. After gaining
informed consent, we tested participants’ understanding
of each of four utility measurement methods: rating scale,
TTO, WTP and SG. We chose these four measurement
strategies based on their use in prior studies because each
has distinct advantages and disadvantages.24
Similar to previous studies, we found that when we
asked test questions using the rating scale method (eg, a
scale of 0–100), participants overestimated the disutility
of taking pills, often assigning utility values of 0.7 or
lower to taking 1 pill/day—a value which would be com-
parable to non-disabling stroke (0.75).7 Additionally, the
rating scale method precludes use of a trade-off when
measuring the disutility. Therefore, we did not retain
this method. Based on pretesting and on past studies,
the TTO seemed to have the best understandability and
face validity; we also retained the SG and WTP to help
provide convergent validity.
Our survey (see online supplementary appendix 1),
which we administered using an online survey site,
consisted of a total of 19 items. Following a consent
page, initial items asked about the respondent’s personal
pill regimen as well as about how specific qualities of
pills (eg, size, shape) affect the difficulty of taking a pill.
Subsequent sections elicited utilities via various
methods. Questions included a series of TTO method
questions, and one question each to assess utility via
WTP method and a modified SG method. For these
assessments, we asked participants to assume the pills
had no side effects and no costs, thus, we were explicitly
testing the isolated utility of taking pills because side
effects and costs should be dealt with separately in a
cost-effectiveness or cost-utility analysis. We included
questions to ascertain the numeracy level25 26 of each
respondent, followed by a final section asking for basic
demographic information.
We pilot tested the survey using a convenience sample
of seven people to gather further feedback on ease of
completion and clarity of questions. Based on feedback,
we refined a few items to maximise clarity.
Participant selection
We recruited participants in two ways. First, an informa-
tional email advertising the study and asking for volun-
teers was sent to all UNC Healthcare employees.
Second, an informational newsletter advertisement was
placed in the UNC Healthcare employee and UNC
School of Medicine newsletters. The email advertise-
ment had a potential reach of 8592, and the newsletter
advertisements had a potential reach of approximately
10 000, but many people receive these in duplicate. The
only criterion for eligibility was age 18 years or older. By
completing the survey, participants were given the
opportunity to enter a draw for a US$200 VISA gift card.
Variables
Our main outcomes were utility values for taking 1 pill/
day, using a TTO utility assessment method. We also
obtained a utility value for taking 1 pill/day using a
modified SG and a modified WTP method, and exam-
ined the utility of taking two pills daily or one pill two
times a day using TTO as well. Participants rated diffi-
culty obtaining medications and difficulty paying for
medications on a scale from 1 to 5. For analysis, these
difficulty levels were then combined into three categor-
ies: not difficult, neutral and difficult. Additionally,
numeracy was assessed using a previously validated three-
question numeracy questionnaire, with overall numeracy
level, then categorised as either ‘low’ if the respondent
got 0–1 correct answers or ‘adequate’ if the respondent
got 2–3 answers correct.25 26
Data analysis
The TTO utility value was derived by dividing the
amount of time each respondent was willing to give up
by the approximate amount of time each respondent
had remaining in his or her life (using an average
life expectancy of 78 years) and subtracting from 1
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(see online supplementary appendix 2). Although other
studies carry out a TTO assessment by varying the
amount of time the respondent is willing to trade until a
point of indifference between the two states is
reached,5 27 28 we modified this method to allow us to
include a single item in the survey. Some survey respon-
dents did not enter age in the survey, which prevented
us from being able to calculate a TTO utility value.
Participants with missing age data (n=95) were excluded
from the TTO analysis.
The utility value for SG was calculated as 1 minus the
risk of death the participant was willing to accept for the
alternate treatment that did not require pill-taking (see
online supplementary appendix 2). Again, in order to
accommodate evaluating utility within a survey, our
assessment was a modified version of other studies’
assessments which vary the gamble of death until a
point of no preference is reached.27 29 The utility value
using WTP was derived by dividing the amount a partici-
pant was willing to pay (to not have to take a pill) by
their total estimated remaining earnings through an
average retirement age of 65 years and subtracting from
1 (see online supplementary appendix 2). We used the
middle value from whichever income category the par-
ticipant selected. We excluded all participants who did
not provide an age (n=95) and those who were older
than 65 years (n=19). The responses received for WTP
varied significantly in range, which led to some utility
values being considerable outliers. Therefore, we also
excluded WTP-based utility values below 0.95 (n=4).
Two of those values were the result of extreme outliers
with corresponding WTP values of US$1 000 000 000
and US$1 000 000. A total of 118 responses were
excluded from the WTP analysis.
Participant responses to TTO, SG and WTP questions
were converted to utility values using Microsoft Excel
(Mac 2011, V.14.1.0. Redmond, Washington, USA), after
which an analysis was performed using STATA V.12
(StataCorp 2011, Stata Statistical Software: Release 12.
College Station, Texas, USA).
We describe basic participant demographics ratings of
pill characteristics and average utility values using pro-
portions with 95% CIs or means with SDs. All utility
values were rounded to four decimal places. The utility
values are not normally distributed (with median values
of 1), but we report means, which is consistent with
prior literature4 and the notion that there is some dis-
utility, albeit small, from pill-taking. We calculated 95%
CIs using 1000 bootstrapped samples. Kruskal-Wallis tests
were used to compare utility values by participant




A total of 758 people opened the survey link, with nine
who declined to provide consent. Of the 749 who gave
consent and began the survey, 708 finished the survey
before it was closed. The rate of completion among all
who opened the survey was 708/749 (∼94.5%). Mean
age of respondents was 43 years, with more participants
in the over 50-year-old category (41%) than either the
18–35 (30%) or the 36–50 (29%) year old categories
(table 1).
Most participants were female (83%) and Caucasian
(80%), and almost all participants had health insurance
(99%). Additionally, almost half had annual household
incomes greater than US$75 000 (48%) with about 85%
having at least a college degree. Approximately 84% had
adequate numeracy, and 61% rated their health as very
good or excellent. Less than 8% of participants reported
any degree of difficulty obtaining their pills, while about
Table 1 Participant characteristics
Characteristic n N (%)
Mean age 613 43 years










<$25 000 43 (6.1)
$25 000–$75 000 323 (45.6)
>$75 000 342 (48.3)
<College degree 708 104 (14.7)
Numeracy 708
0 correct 31 (4.4)
1 correct 84 (11.9)
2 correct 231 (32.6)





Very good 317 (44.8)
Excellent 113 (16.0)
Percentage of insured 708 698 (98.6)
Difficulty obtaining pills† 708
Somewhat difficult 52 (7.3)
Very difficult 3 (0.4)
Difficulty paying for pills† 708
Somewhat difficult 106 (15.0)
Very difficult 8 (1.1)
Number of times pills taken per day ≥2 708 358 (50.6)






†Rated on five-point scale.
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16% of participants reported some degree of difficulty
paying for their pills. Approximately 65% took at least 3
pills/day, while only 3.7% took no pills per day.
TTO utility value
The average amount of time participants were willing to
trade instead of having to take 1 pill/day was 5.0 weeks,
which translated to a utility of 0.9972 (table 2).
Approximately 87% of respondents indicated that they
would not trade any time (ie, utility of 1.0) in exchange
for not having to take 1 pill/day (figure 1). Mean utility
value was not significantly different by age, sex, race or
education level (table 3). Respondents with lower
income levels had lower mean utility values.
We also noted differences based on difficulty obtain-
ing pills, difficulty paying for pills, and number of pills
taken per day. Although not statistically significant, the
small number of respondents who indicated currently
taking no daily pills had a lower mean value for utility of
taking pills than those who took at least 1 pill/day, a dif-
ference that would likely have meaningful effects on
cost-effectiveness analyses.
SG utility value
Using an SG method, 57.5% of respondents (figure 2)
indicated that they would take no chance of immediate
death (0 in 1 000 000), translating to a utility value of
1.0. The overall average utility value derived by SG for
taking 1 pill/day was 0.9967 (table 2). Mean utility value
by SG varied slightly by age, sex and education level
(table 4).
As with the TTO, those who took no daily pills
assigned a lower utility value to taking pills than those
who took at least 1 pill/day, although the difference was
not statistically significant.
WTP utility value
Using the WTP method, 9.5% of respondents (figure 2)
indicated that they would pay nothing (US$0), translat-
ing to a utility value of 1.0. The mean amount that
respondents were willing to pay to not have to take 1
pill/day, excluding those with missing age data and out-
liers, was US$1359. Using this WTP value, the overall
average utility for taking 1 pill/day was 0.9989 (table 2).
Mean utility value by WTP varied slightly by age, race
and education level (table 4). Those with a lower numer-
acy level assigned a higher mean utility value by WTP
(0.9994 vs 0.9988, p<0.001).
Table 2 Average utility value for each outcome
Assessment method Utility value (95% CI)
Time trade-off*
1 pill/day 0.9972 (0.9962 to 0.9980)
2 pills/day 0.9969 (0.9958 to 0.9977)
1 pill two times a day 0.9965 (0.9955 to 0.9973)
Standard gamble
1 pill/day 0.9967 (0.9954 to 0.9979)
Willingness-to-pay†‡
1 pill/day 0.9989 (0.9986 to 0.9991)
*Participants with missing age data removed prior to calculating
mean and SD (95 responses removed).
†Participants with missing age data (n=95) and age ≥65 (n=19)
removed prior to calculating mean and SD (114 responses
removed).
‡Outliers below 0.95 were removed from data prior to calculating
mean and SD (4 responses removed).
Figure 1 Distribution of Time Trade-Off Responses. As seen in the figure, 87.4% of respondents were not willing to trade any
time in exchange for not having to take a daily pill. Approximately 3% would trade 2 years.
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Pill characteristics
Pill size was the most important characteristic affecting
difficulty of pill-taking, with a mean score of 3.06 on a
scale of 1–5 where five represents the greatest influence
on difficulty (table 5). Shape was the least important
characteristic with a mean score of 2.23.
DISCUSSION
In a sample of 708 participants, we found the utility of
taking a pill daily for CVD prevention to be 0.997. This
value was similar across multiple utility methods, each
with its own theoretical strengths and weaknesses, as well
as across multiple subgroups, and is consistent with the
two previous small studies done using the TTO
method.7 8 The value is slightly higher than the range of
values of 0.990–0.994 we found in our subsequent
study.23 Our subsequent study, however, used a national
sample with a higher mean age, a larger proportion of
men, and wider range of education levels.
It is important to note that our intent was to specific-
ally measure the hassle of daily pill-taking, separate from
the issue of the pill’s effectiveness. We accomplished this
by asking respondents to consider what they would
Table 3 Mean utility values by participant characteristics*
Characteristic n
1 Pill/day 2 Pills/day 1 Pill two times a day
Mean p Value† Mean p Value† Mean p Value†
Age (years)
18–35 211 0.9987 0.313 0.9983 0.416 0.9975 0.141
36–50 206 0.9962 0.9957 0.9957
>50 196 0.9966 0.9965 0.9962
Sex
Female 519 0.9974 0.258 0.9970 0.903 0.9966 0.906
Male 94 0.9959 0.9963 0.9959
Race
African–American 68 0.9964 0.142 0.9954 0.093 0.9949 0.313
Caucasian 492 0.9974 0.9972 0.9969
Other 53 0.9959 0.9959 0.9949
Education level
<College degree 84 0.9974 0.593 0.9971 0.416 0.9970 0.090
College or graduate degree 529 0.9972 0.9969 0.9964
Income
<$25 000 33 0.9953 0.005 0.9945 0.006 0.9943 0.012
$25 000–$75 000 277 0.9972 0.9969 0.9965
>$75 000 303 0.9974 0.9971 0.9968
Health rating
<Very good 227 0.9967 0.810 0.9961 0.545 0.9963 0.677
≥Very good 386 0.9975 0.9973 0.9966
Numeracy level‡
Low 93 0.9952 0.736 0.9936 0.182 0.9941 0.875
Adequate 520 0.9975 0.9975 0.9969
Difficulty obtaining pills
Not difficult 517 0.9976 0.008 0.9973 0.011 0.9968 0.061
Neutral 51 0.9924 0.9935 0.9939
Difficult 45 0.9978 0.9957 0.9966
Difficulty paying for pills
Not difficult 435 0.9978 0.014 0.9977 0.019 0.9971 0.038
Neutral 83 0.9935 0.9933 0.9933
Difficult 95 0.9979 0.9965 0.9966
Number of times pills taken per day
<2 303 0.9963 0.003 0.9961 0.034 0.9955 0.007
≥2 310 0.9980 0.9976 0.9975
Number of pills taken per day
0 25 0.9936 0.094 0.9944 0.233 0.9941 0.268
1 99 0.9969 0.9966 0.9956
2 96 0.9987 0.9980 0.9976
3+ 393 0.9971 0.9968 0.9966
*Utilities derived using time trade-off technique.
†p Values based on Kruskal-Wallis test.
‡Numeracy level based on number of questions correct on numeracy question (0–1=low; 2–3=adequate).
Hutchins R, et al. BMJ Open 2015;5:e006505. doi:10.1136/bmjopen-2014-006505 5
Open Access
‘trade’ for achieving the preventive benefit without
requiring daily pill-taking (compared with achieving the
benefit but having to take a daily pill). Ideally, respon-
dents thought about all the steps involved in pill-taking,
including visits to obtain the prescription, visits to the
pharmacy, and actually having to take the pills every day.
In other words, we sought to measure the overall health
state (utility value) of ‘daily pill-taking’.
The utility value of taking a pill daily can have an
important effect on cost-effectiveness analyses. Even rela-
tively small decrements in utility like those found in this
study can have important effects on quality-adjusted life
years (QALYs) for interventions in healthy people where
the frequency of outcomes is low. For example, one
study examined whether cost-effectiveness of aspirin was
sensitive to the assigned utility value of taking the pill.1
The base case used a utility value of 1.0; the authors
then examined the cost per QALY gained across a
variety of utility values for taking aspirin. In that analysis,
using any utility value below about 0.9996 caused a large
increase in the cost per QALY, above the arbitrary but
commonly used threshold of US$50 000/QALY for
patients at relatively modest baseline cardiovascular
disease (CVD) risk. Another study examined the cost-
effectiveness of the management of chronic non-valvular
atrial fibrillation with no treatment, aspirin or warfarin.2
Although the authors used a base case utility value of
0.99 for warfarin, they performed a one-way sensitivity
analysis varying that utility value from 0.95 to 1.0. The
authors found that the results were very sensitive to the
assigned utility of taking warfarin. Over that range, the
outcome varied from making warfarin the most favoured
strategy to the least favoured strategy (compared with
aspirin). A third study used a base case utility value of
0.999 for taking a statin daily for 10 years and found a
cost/QALY gain of US$34 995 for a 55-year-old man.3
Assuming no disutility from taking a pill and altering that
utility value to only 1.0, the cost/QALY decreases nearly
25% to US$26 394. Such analyses highlight the import-
ance of having an accurately measured utility value for
pill-taking, rather than simply relying on arbitrary levels
or expert opinion, as has been done previously.
Our results are comparable to two prior studies that
measured a utility value for pill-taking, though our study
sample is 10 times larger in number.7 8 Our utility value
of 0.997 is similar to the value of 0.998 found in prior
studies for taking aspirin, and is higher than the values
for taking warfarin noted in prior studies: 0.987 and
0.988. The lower values for taking warfarin are likely
due to those studies including within the utility of taking
the pill the additional utility of the INR monitoring and
lifestyle limitations such as avoidance of excessive
alcohol and contact sports. We sought to examine the
utility of the daily pill-taking process itself, viewing
aspects such as bothersome side effects, activity limita-
tions, and any required therapeutic monitoring as separ-
ate issues, which would vary from pill to pill.
We are aware of at least 17 additional studies that use a
utility value of taking pills in their analyses. All these
studies cited values between 0.95 and 1.0, depending on
Figure 2 Distribution of Standard Gamble Responses. As seen in the figure, 57.5% of respondents were not willing to risk any
chance of immediate death for not having to take a daily pill. Approximately 3% accept a 10% risk.
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the type of pill and whether or not side effects and mon-
itoring were considered.1–3 8–21 Most of the studies used
a value close to 1.0 as their base case and then per-
formed a sensitivity analysis to analyse a range. The
lower end of the range of most sensitivity analyses was
generally lower than the values that we obtained in this
study.
For ‘difficulty obtaining pills’ and ‘difficulty paying for
pills’ (table 3), the ‘neutral’ category respondents had a
lower mean utility than ‘not difficult’ and ‘difficult’.
This counterintuitive finding likely arose from chance.
As expected, as the pill regimen becomes more complex
and time-consuming, the utility decreases. From 1 to 2
pills/day to 1 pill two times a day, the utility value incre-
mentally decreased from 0.9972 to 0.9969 to 0.9965,
respectively, using the TTO method. The SG and WTP
methods revealed similar values of 0.9967 and 0.9989,
respectively. These findings, along with our results in
table 5, suggest that two things that can be done to min-
imise the impact of pill-taking on quality of life are
keeping pill regimens simple (ie, once daily) and
making pills small in size.
Table 4 Mean utility value of taking 1 pill/day by participant characteristics*
Characteristic
Standard gamble Willingness-to-pay†,‡
n Mean p Value* n Mean p Value*
Age (years)
18–35 211 0.9966 0.003 210 0.9989 0.017
36–50 206 0.9973 204 0.9992
>50 291 0.9963 176 0.9985
Sex
Female 590 0.9966 0.006 504 0.9989 0.119
Male 118 0.9974 86 0.9985
Race
African–American 80 0.9934 0.225 68 0.9992 0.010
Caucasian 565 0.9973 472 0.9989
Other 63 0.9957 50 0.9985
Education level
<College degree 104 0.9950 0.011 80 0.9993 0.012
College or graduate degree 604 0.9970 510 0.9988
Income level
<$25 000 43 0.9971 0.713 30 0.9963 0.164
$25 000–$75 000 323 0.9966 269 0.9989
>$75 000 342 0.9968 291 0.9991
Health rating
<Very good 278 0.9964 0.167 220 0.9987 0.314
≥Very good 430 0.9969 370 0.9989
Numeracy level§
Low 115 0.9919 0.059 91 0.9994 <0.001
Adequate 593 0.9976 499 0.9988
Difficulty obtaining pills
Not difficult 594 0.9971 0.316 497 0.9989 0.147
Neutral 59 0.9962 49 0.9985
Difficult 55 0.9925 44 0.9990
Difficulty paying for pills
Not difficult 493 0.9976 0.682 418 0.9988 0.545
Neutral 101 0.9969 80 0.9991
Difficult 114 0.9925 92 0.9990
Number of times pills taken per day
<2 350 0.9961 0.263 297 0.9989 0.998
≥2 358 0.9973 293 0.9989
Number of pills taken per day
0 26 0.9953 0.107 25 0.9979 0.792
1 113 0.9965 98 0.9990
2 110 0.9989 93 0.9987
3+ 459 0.9963 374 0.9989
Utilities derived using standard gamble technique or willingness-to-pay technique, as indicated.
*p Values based on Kruskal-Wallis test.
†Participants with missing age data (n=95) and age ≥65 (n=19) removed prior to calculating mean and p value (114 responses removed).
‡Outliers below 0.95 were removed from data prior to calculating mean and p value (4 responses removed).
§Numeracy level based on number of questions correct on numeracy question (0–1=low; 2–3=adequate).
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Strengths and limitations
To the best of our knowledge, this study and our subse-
quent national study23 are the largest studies to date to
quantify the utility of pill-taking. The large sample
allowed us to examine multiple subgroups, an important
strength of our study over two previous studies that
included fewer than 100 participants each. An additional
strength of our study is its use of three different utility
assessments.
We found that at least some participants were willing
to make trade-offs (ie, had utility values other than 1.0)
by each of the methods, including over 90% of partici-
pants with WTP. The low number of people who would
not trade any time (∼9%) is a strength of this method
and provides indirect support for using it. We had
hypothesised that WTP may be a particularly good
method for this type of utility assessment, and our find-
ings suggest promise for its use in other situations
requiring the measurement of small decrements in
utility. Moreover, our results did not differ greatly
between these two methods, providing even further
support that our results are sound.
Limitations
We also acknowledge several limitations. Our respon-
dents were predominantly women, and most had at least
a college degree. We noted small differences in mean
utility values across some of the characteristics in our
sample. Also, our sample was not representative of the
general population.
To make our survey feasible and increase the chance
of yielding accurate results, we modified the administra-
tion of utility assessment methods. Our WTP analysis was
modified to adjust for lifetime earnings and did not
account for any participants over the typical retirement
age of 65 years and also does not account for any
income over the age of 65 years. It also assumes that a
person’s annual income remains stable over a lifetime.
Despite these simplifications, our results converged with
our other methods.
Because we used 78 years as the mean life expectancy
for our calculation of TTO, if a participant expected to
live longer than 78 years and responded as such, our
final utility value could have been smaller than their
‘true’ value, indicating more effect on quality of life
than in reality. Again, this did not appear to have a
major effect on results.
We did not assess test–retest reliability. Utility values
may fluctuate over time as individuals adapt to a given
health state. Our survey only measured individuals’ pre-
ferences at one point in time. We note that the differ-
ences in results based on previous pill-taking suggest
that utility values will change in meaningful ways.
Although we stipulated in our survey instrument that
participants would not have to pay for pills and to
ignore any potential side effects, we cannot be certain
that these issues did not have an effect on participant
responses, which could have introduced some error in
our utility estimates. We presented items in the survey
about problems people may experience when taking
daily pills. These items preceded the utility items
because we wanted respondents to be cognitively pre-
pared to report their true values. It is possible, though
unlikely, that such information may have introduced
bias. A future study could randomise the order of survey
items. Also, given the added survey response burden it
would have created, we chose not to include a method
such as the EQ-5D in measuring the disutility of daily
pill-taking. Future studies could compare our methods
to quality of life scales such as the EQ-5D.
Finally, our utility assessment questions used set inter-
vals in a multiple-choice format rather than allowing
respondents to input (‘free-text’) their answers.
However, the options we provided were within a reason-
able range of the magnitude of answers we were expect-
ing based on our focus group, pilot testing and
literature review. Additionally, ‘forced-choice’ methods
are preferable when using health-related quality of life
instruments.24
CONCLUSIONS
The utility value of taking a pill daily to try to prevent an
adverse CVD health outcome is approximately 0.997.
Knowing this value is useful for researchers evaluating
preventive interventions for CVD that include taking
pills, including the decision about taking aspirin or
statins, and should be considered in addition to informa-
tion about the decrements in utility from adverse out-
comes such as gastrointestinal bleeding or myopathy.
Finally, this study reminds clinicians that patients appre-
ciate once-daily pill regimens and small pills.
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